Literature DB >> 15646658

Unmanipulated reduced-intensity stem cell transplantation from a haploidentical donor mismatched at 3 HLA antigens to a patient with leukemic transformation of myelodysplastic syndrome: successful second transplantation after graft rejection.

Eui Ho Kim1, Kazuhiro Ikegame, Manabu Kawakami, Sumiyuki Nishida, Tatsuya Fujioka, Yuki Taniguchi, Tomoki Masuda, Yoshihiro Oka, Ichiro Kawase, Hiroyasu Ogawa.   

Abstract

We present the case of a patient with myelodysplastic syndrome who experienced leukemia transformation and subsequently underwent transplantation of unmanipulated peripheral blood stem cells from a haploidentical sibling mismatched at 3 HLA antigens, along with a reduced-intensity regimen (fludarabine, busulfan, and anti-T-lymphocyte globulin) and tacrolimus-containing graft-versus-host disease (GVHD) prophylaxis. The patient experienced graft rejection but successfully underwent a second transplantation from the same donor with a slightly intensified conditioning regimen. Although the patient developed life-threatening cytomegalovirus (CMV) pneumonia following the second transplantation, he recovered completely from the pneumonia with intensive supportive therapy. He is still in complete remission past day 1000 in the absence of GVHD. As far as we know, this report is the first to describe a successful second transplantation that was performed for graft rejection following HLA-haploidentical nonmyeloablative stem cell transplantation. Furthermore, we emphasize that patients should be carefully monitored for CMV infection when reduced-intensity conditioning is given repeatedly over a short period.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15646658     DOI: 10.1532/ijh97.04100

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

1.  Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin.

Authors:  H Tamaki; K Ikegame; M Kawakami; T Fujioka; A Tsuboi; Y Oji; Y Oka; H Sugiyama; I Kawase; H Ogawa
Journal:  Leukemia       Date:  2003-10       Impact factor: 11.528

Review 2.  Pathophysiologic mechanisms of acute graft-vs.-host disease.

Authors:  J L Ferrara; R Levy; N J Chao
Journal:  Biol Blood Marrow Transplant       Date:  1999       Impact factor: 5.742

3.  Rapid diagnosis of cytomegalovirus infections by direct immunoperoxidase staining with human monoclonal antibody against an immediate-early antigen.

Authors:  Y Eizuru; T Minematsu; Y Minamishima; K Ebihara; K Takahashi; K Tamura; K Hosoda; Y Masuho
Journal:  Microbiol Immunol       Date:  1991       Impact factor: 1.955

4.  Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation.

Authors:  G E Georges; R Storb; J D Thompson; C Yu; T Gooley; B Bruno; R A Nash
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

5.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

Authors:  S Giralt; E Estey; M Albitar; K van Besien; G Rondón; P Anderlini; S O'Brien; I Khouri; J Gajewski; R Mehra; D Claxton; B Andersson; M Beran; D Przepiorka; C Koller; S Kornblau; M Kørbling; M Keating; H Kantarjian; R Champlin
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

6.  Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis.

Authors:  H J Deeg; T R Spitzer; M Cottler-Fox; R Cahill; L W Pickle
Journal:  Bone Marrow Transplant       Date:  1991-03       Impact factor: 5.483

7.  Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.

Authors:  M Bornhäuser; C Thiede; U Platzbecker; A Jenke; A Helwig; R Plettig; J Freiberg-Richter; C Röllig; G Geissler; K Lutterbeck; U Oelschlagel; G Ehninger
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

8.  Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation.

Authors:  M Sykes; F Preffer; S McAfee; S L Saidman; D Weymouth; D M Andrews; C Colby; R Sackstein; D H Sachs; T R Spitzer
Journal:  Lancet       Date:  1999-05-22       Impact factor: 79.321

9.  Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling.

Authors:  Jon J van Rood; Fausto R Loberiza; Mei-Jie Zhang; Machteld Oudshoorn; Frans Claas; Mitchell S Cairo; Richard E Champlin; Robert Peter Gale; Olle Ringdén; Jill M Hows; Mary H Horowitz
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

10.  Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies.

Authors:  Thomas R Spitzer; Steven L McAfee; Bimalangshu R Dey; Christine Colby; James Hope; Howard Grossberg; Frederic Preffer; Juanita Shaffer; Stephen I Alexander; David H Sachs; Megan Sykes
Journal:  Transplantation       Date:  2003-05-27       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.